EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214

David Cella iD, Toni K Choueiri iD, Melissa Hamilton, Steven I Blum, Cristina Ivanescu, Karl Karu, Flavia Ejzykowicz, Robert J Motzer

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae003 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Oncologist, 2024. Verfasst von David Cella und 7 weiteren Autor:innen. Beteiligte Einrichtung: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Quality of Life, Kidney Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In CheckMate 214 (median follow-up, 25.2 months), nivolumab plus ipilimumab yielded greater overall survival (OS) benefit than sunitinib in patients with intermediate-/poor-risk advanced renal cell carcinoma (aRCC). Health-related quality of life (HRQoL) assessed by the Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 (FKSI-19) was also more favorable for the nivolumab plus ipilimumab group than the sunitinib group. We investigated whether HRQoL scores can predict OS of patients with 5 years follow-up in CheckMate 214. Patients and Methods CheckMate 214 was an open-label, phase III trial in previously untreated aRCC (N = 1096). Patients with intermediate-/poor-risk disease (International mRCC Database Consortium prognostic score ≥ 1; n = 847) were randomized to either nivolumab plus ipilimumab or sunitinib monotherapy. Pooled data for OS and FKSI-19 total and subscales (disease-related symptoms [DRS], DRS-physical [DRS-P], and function/well-being [FWB]) were analyzed. Relationships between HRQoL and OS were assessed using Cox proportional hazard models with baseline and longitudinal scores. Associations between HRQoL changes and OS were assessed by landmark analyses.

Results

Patients with higher FKSI-19 total and subscale scores at baseline had longer OS than patients with lower scores (HR ≤ 0.834; P < .0001). Longitudinal models indicated stronger associations between HRQoL and OS (HR ≤ 0.69; P < .001 for each). At 3 months after randomization, patients with stable/improved HRQoL versus baseline had longer median OS than patients with worsened/unobserved HRQoL versus baseline (55.9 and 26.0 months, respectively; HR = 0.56; 95% CI, 0.46-0.67; P < .0001). Results at 6-, 9-, and 12-month landmarks were consistent with these findings.

Conclusion

In aRCC, patient-reported outcomes are important for HRQoL and prognostic evaluation. Clinicaltrials.gov Identifier NCT02231749; https://clinicaltrials.gov/ct2/show/NCT02231749.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellQuality of LifeKidney NeoplasmsHumansMaleFemaleMiddle AgedAgedSunitinibAntineoplastic Combined Chemotherapy ProtocolsIpilimumabNivolumabAdult

Stichwörter der Autor:innen

health-related quality of lifeimmune checkpoint inhibitorspatient-reported outcome measuresprognosisrenal cell carcinomasurvival

Substanzen

SunitinibIpilimumabNivolumab

Autor:innen und Institutionen

  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
  • Dana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology, Boston, MA, USA.
  • Bristol Myers Squibb, Princeton, NJ, USA.
  • IQVIA, Amsterdam, The Netherlands.
  • IQVIA, Tartu, Estonia.
  • Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: David Cella, Toni K Choueiri

Förderung

  • NCI NIH HHS
  • Bristol-Myers Squibb

Zitieren

APA

Cella, D., Choueiri, T. K., Hamilton, M., Blum, S. I., Ivanescu, C., Karu, K., Ejzykowicz, F., & Motzer, R. J. (2024). The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214. The Oncologist. https://doi.org/10.1093/oncolo/oyae003

Vancouver

Cella D, Choueiri TK, Hamilton M, Blum SI, Ivanescu C, Karu K, et al. The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214. The Oncologist. 2024. doi:10.1093/oncolo/oyae003

BibTeX
@article{Cella2024,
  author = {Cella, David and Choueiri, Toni K and Hamilton, Melissa and Blum, Steven I and Ivanescu, Cristina and Karu, Karl and Ejzykowicz, Flavia and Motzer, Robert J},
  title = {The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae003}
}
Kostenlos starten →